Editorial
doi: 10.1136/bmj.38797.635012.47.
Epub 2006 Mar 22.
Learning from the TGN1412 trial
- PMID: 16554332
- PMCID: PMC1410845
- DOI: 10.1136/bmj.38797.635012.47
Item in Clipboard
Editorial
Learning from the TGN1412 trial
BMJ.
.
Abstract
This experience should foster an open culture in medical research
Similar articles
-
Severe adverse reactions prompt call for trial design changes.BMJ. 2006 Mar 25;332(7543):683. doi: 10.1136/bmj.332.7543.683. BMJ. 2006. PMID: 16565101 Free PMC article. No abstract available.
-
TeGenero fiasco prompts regulatory rethink.Nat Biotechnol. 2006 May;24(5):475-6. doi: 10.1038/nbt0506-475. Nat Biotechnol. 2006. PMID: 16680111 No abstract available.
-
[Why has the drug trial at Northwick Park Hospital turned out to a disaster?].Lakartidningen. 2006 Apr 12-25;103(15-16):1169-70. Lakartidningen. 2006. PMID: 16696196 Swedish. No abstract available.
-
Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.Int J Clin Pharmacol Ther. 2007 Jan;45(1):1-9. doi: 10.5414/cpp45001. Int J Clin Pharmacol Ther. 2007. PMID: 17256444 Review.
-
[Informed consent in phase I trial].Gan To Kagaku Ryoho. 1996 Jan;23(2):226-30. Gan To Kagaku Ryoho. 1996. PMID: 8611051 Review. Japanese.
Cited by
-
Biological therapies: concepts and challenges.Wien Klin Wochenschr. 2006 Sep;118(17-18):508-12. doi: 10.1007/s00508-006-0670-6. Wien Klin Wochenschr. 2006. PMID: 17009061 No abstract available.
-
Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.Drug Saf. 2006;29(8):657-73. doi: 10.2165/00002018-200629080-00003. Drug Saf. 2006. PMID: 16872240 Review.
-
Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.BMC Immunol. 2009 Sep 28;10:52. doi: 10.1186/1471-2172-10-52. BMC Immunol. 2009. PMID: 19785746 Free PMC article.
-
Marching ahead with clinical trial registration.Indian J Ophthalmol. 2008 May-Jun;56(3):175-6. doi: 10.4103/0301-4738.40353. Indian J Ophthalmol. 2008. PMID: 18417815 Free PMC article. No abstract available.
-
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature.Immunotherapy. 2024;16(18-19):1113-1122. doi: 10.1080/1750743X.2024.2422814. Epub 2024 Nov 21. Immunotherapy. 2024. PMID: 39569624 Review.
References
-
- Pearson H. Tragic drug trial spotlights potent molecule. Nature doi: 10.1038/news060313-17 (published 17 March 2006). - DOI
-
- Beyersdorf N, Hanke T, Kerkau T, Hunig T. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. Autoimmun Rev 2006;5: 40-5. - PubMed
-
- Kennedy I. Learning from Bristol: the report of the public inquiry into children's heart surgery at the Bristol Royal Infirmary 1984-1995. London: Stationery Office, 2001. (Cm 5207.)
-
- Merton RK. Unanticipated consequences of purposive social action. Am Sociol Rev 1936;1:894-904. www.compilerpress.atfreeweb.com/Anno%20Merton%20Unintended.htm (accessed 21 Mar 2006).
-
- Oakeshott I, Rogers L. Earlier trials had shown that drug group was highly toxic. Sunday Times 2006 Mar 19. www.timesonline.co.uk/article/0,,2087-2092619,00.html (accessed 21 Mar 2006).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
